NFATc1 Promotes Prostate Tumorigenesis and Overcomes PTEN Loss-induced Senescence
Overview
Authors
Affiliations
Despite recent insights into prostate cancer (PCa)-associated genetic changes, full understanding of prostate tumorigenesis remains elusive owing to complexity of interactions among various cell types and soluble factors present in prostate tissue. We found the upregulation of nuclear factor of activated T cells c1 (NFATc1) in human PCa and cultured PCa cells, but not in normal prostates and non-tumorigenic prostate cells. To understand the role of NFATc1 in prostate tumorigenesis in situ, we temporally and spatially controlled the activation of NFATc1 in mouse prostate and showed that such activation resulted in prostatic adenocarcinoma with features similar to those seen in human PCa. Our results indicate that the activation of a single transcription factor, NFATc1 in prostatic luminal epithelium to PCa can affect expression of diverse factors in both cells harboring the genetic changes and in neighboring cells through microenvironmental alterations. In addition to the activation of oncogenes c-MYC and STAT3 in tumor cells, a number of cytokines and growth factors, such as IL1β, IL6 and SPP1 (osteopontin, a key biomarker for PCa), were upregulated in NFATc1-induced PCa, establishing a tumorigenic microenvironment involving both NFATc1 positive and negative cells for prostate tumorigenesis. To further characterize interactions between genes involved in prostate tumorigenesis, we generated mice with both NFATc1 activation and Pten inactivation in prostate. We showed that NFATc1 activation led to acceleration of Pten null-driven prostate tumorigenesis by overcoming the PTEN loss-induced cellular senescence through inhibition of p21 activation. This study provides direct in vivo evidence of an oncogenic role of NFATc1 in prostate tumorigenesis and reveals multiple functions of NFATc1 in activating oncogenes, in inducing proinflammatory cytokines, in oncogene addiction, and in overcoming cellular senescence, which suggests calcineurin-NFAT signaling as a potential target in preventing PCa.
PPP3CB overexpression mediates EGFR TKI resistance in lung tumors via calcineurin/MEK/ERK signaling.
Gazzeri S, Zubchuk N, Montaudon E, Nemati F, Huot-Marchand S, Berardi G Life Sci Alliance. 2024; 7(12).
PMID: 39353739 PMC: 11447527. DOI: 10.26508/lsa.202402873.
Xiong Y, Huang W, Ling X, Zhou S, Wang X, Li X Acta Pharmacol Sin. 2024; 45(10):2149-2162.
PMID: 38789496 PMC: 11420221. DOI: 10.1038/s41401-024-01298-5.
Yang H, Zhou J, He K, Li J, Zhao F, Dai N J Cancer. 2023; 14(12):2361-2372.
PMID: 37576400 PMC: 10414045. DOI: 10.7150/jca.84307.
Thrombin Cleavage of Osteopontin and the Host Anti-Tumor Immune Response.
Leung L, Myles T, Morser J Cancers (Basel). 2023; 15(13).
PMID: 37444590 PMC: 10340489. DOI: 10.3390/cancers15133480.
Lin W, Xiong J, Jiang Y, Liu H, Bian J, Wang J Channels (Austin). 2023; 17(1):2192377.
PMID: 36972239 PMC: 10054150. DOI: 10.1080/19336950.2023.2192377.